Guillain Barre Syndrome Pipeline Insight

DelveInsight’s, “Guillain-Barre Syndrome – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Guillain-Barre Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Guillain-Barre Syndrome Understanding

Guillain-Barre Syndrome: Overview

Guillain-Barré syndrome (GBS) is a rare condition in which a person’s immune system attacks the peripheral nerves. Guillain-Barré syndrome is potentially life-threatening. People with Guillain-Barré syndrome should be treated and monitored; some may need intensive care. Treatment includes supportive care and some immunological therapies. In Guillain-Barré syndrome, the body's immune system attacks part of the peripheral nervous system. The syndrome can affect the nerves that control muscle movement as well as those that transmit pain, temperature and touch sensations. This can result in muscle weakness and loss of sensation in the legs and/or arms. It is a rare condition, and while it is more common in adults and in males, people of all ages can be affected. Diagnosis is based on symptoms and findings on neurological examination including diminished or loss of deep-tendon reflexes.


"Guillain-Barre Syndrome - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Guillain-Barre Syndrome pipeline landscape is provided which includes the disease overview and Guillain-Barre Syndrome treatment guidelines. The assessment part of the report embraces, in depth Guillain-Barre Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Guillain-Barre Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Guillain-Barre Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Guillain-Barre Syndrome.

Guillain-Barre Syndrome Emerging Drugs Chapters

This segment of the Guillain-Barre Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Guillain-Barre Syndrome Emerging Drugs


Eculizumab: Alexion Pharmaceuticals

Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. Inhibition of this complex prevents complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobunuria, complement mediated microangiopathy in atypical hemolytic uremic syndrome, and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder. The drug is currently being evaluated in Phase III stage of development.


ANX005: Annexon

ANX005 is an IV formulated monoclonal antibody designed to inhibit C1q and the entire classical complement pathway. ANX005 is intended to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. Annexon has completed a Phase Ib monotherapy clinical trial of ANX005 in GBS and has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for the treatment of GBS.

Further product details are provided in the report……..

Guillain-Barre Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Guillain-Barre Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Guillain-Barre Syndrome

There are approx. 5+ key companies which are developing the therapies for Guillain-Barre Syndrome. The companies which have their Guillain-Barre Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Alexion Pharmaceuticals.


DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Guillain-Barre Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Guillain-Barre Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Guillain-Barre Syndrome therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Guillain-Barre Syndrome drugs.

Guillain-Barre Syndrome Report Insights

  • Guillain-Barre Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Guillain-Barre Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Guillain-Barre Syndrome drugs?
  • How many Guillain-Barre Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Guillain-Barre Syndrome?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Guillain-Barre Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Guillain-Barre Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Guillain-Barre Syndrome: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Eculizumab: Alexion Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ANX005: Annexon

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early stage products (Phase I/II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Guillain-Barre Syndrome Key Companies

Guillain-Barre Syndrome Key Products

Guillain-Barre Syndrome- Unmet Needs

Guillain-Barre Syndrome- Market Drivers and Barriers

Guillain-Barre Syndrome- Future Perspectives and Conclusion

Guillain-Barre Syndrome Analyst Views

Guillain-Barre Syndrome Key Companies


List of Table

Table 1: Total Products for Guillain-Barre Syndrome

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Guillain-Barre Syndrome

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Product

• Alexion Pharmaceuticals
• Annexon, Inc.
• Hansa Biopharma
• Cellenkos, Inc.
• Immunic


Forward to Friend

Need A Quote